Compare GIC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIC | VOR |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1996 | 2021 |
| Metric | GIC | VOR |
|---|---|---|
| Price | $39.54 | $23.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | 102.7K | ★ 946.2K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $1,379,100,000.00 | N/A |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | $28.75 | ★ N/A |
| Revenue Growth | ★ 4.80 | N/A |
| 52 Week Low | $26.40 | $1.62 |
| 52 Week High | $40.26 | $49.95 |
| Indicator | GIC | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 79.07 | 71.43 |
| Support Level | $29.12 | $11.62 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.13 | 1.54 |
| MACD | 0.37 | 0.28 |
| Stochastic Oscillator | 91.42 | 98.66 |
Global Industrial Co is a value-added industrial distributor. The company distributes a wide range of industrial and maintenance, repair, and operations (MRO) products to customers across North America, including storage and shelving, safety and security, carts and trucks, HVAC and fans, furniture and decor, material handling, janitorial and facility maintenance, workbenches and shop desks, tools and instruments, plumbing and pumps, office and school supplies, packaging and shipping, lighting and electrical, food service and retail, medical and laboratory, motors and power transmission, building supplies, machining, fasteners and hardware, vehicle maintenance, and raw material.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.